ArticleMicrobiology spectrum2024
Exploiting phage-antibiotic synergies to disrupt
Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Vancomycin and phage COP-80B combination therapy for Staphylococcus epidermidis periprosthetic joint infections: a preclinical mouse study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Short-Term Bacteriophage Exposure Is Associated with Shifts in Antibiotic Susceptibility Profiles of ClinicalMicroorganisms · 2026Article
- The Pharmacology of Bacterial Persistence: From Antibiotic Tolerance to Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- The infectome framework: linking polymicrobial ecology and biofilm dynamics to precision diagnostic approaches.Infection · 2026Review
- UnderstandingMicroorganisms · 2026Review
- Characterisation of a NovelPathogens (Basel, Switzerland) · 2025Article
- Bacteriophages and Their Enzymes: Allies Against Microbial Biofilms.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Recent advances in the understanding, detection and therapeutic targeting of bacterial recalcitrance.BMC microbiology · 2025Review
- Efficacy of phage vB_Ps_ZCPS13 in controlling Pan-drug-resistant Pseudomonas aeruginosa from urinary tract infections (UTIs) and eradicating biofilms from urinary catheters.Virology journal · 2025Article
- Phage-Antibiotic Combinations for Pseudomonas: Successes in the Clinic and In Vitro Tenuously Connected.Microbial biotechnology · 2025Review
- OvercomingAntibiotics (Basel, Switzerland) · 2025Review
- Phage-phage competition and biofilms affect interactions between two virulent bacteriophages and Pseudomonas aeruginosa.The ISME journal · 2025Article
- Phage therapy as a revitalized weapon for treating clinical diseases.Microbiome research reports · 2025Review
- Phage (cocktail)-antibiotic synergism: a new frontier in addressingFrontiers in microbiology · 2025Article
- Synergistic effects of bacteriophage cocktail and antibiotics combinations against extensively drug-resistant Acinetobacter baumannii.BMC infectious diseases · 2024Article
- Bacteriophage Therapy on an In Vitro Wound Model and Synergistic Effects in Combination with Beta-Lactam Antibiotics.Antibiotics (Basel, Switzerland) · 2024Article
- Bacterial persisters: molecular mechanisms and therapeutic development.Signal transduction and targeted therapy · 2024Review
- Benefits and Challenges of Applying Bacteriophage Biocontrol in the Consumer Water Cycle.Microorganisms · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
importanceBiofilm-related infections are among the most difficult-to-treat infections in all fields of medicine due to their antibiotic tolerance and persistent character. In the field of orthopedics, these biofilms often lead to therapeutic failure of medical implantable devices and urgently need novel treatment strategies. This forthcoming article aims to explore the dynamic interplay between newly isolated bacteriophages and routinely used antibiotics and clearly indicates synergetic patterns when used as a dual treatment modality. Biofilms were drastically more reduced when both active agents were combined, thereby providing additional evidence that phage-antibiotic combinations lead to synergism and could potentially improve clinical outcome for affected patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.